In addition, a recent study on stiff-person syndrome with comorbid myasthenia gravis found that efgartigimod may be a candidate for the treatment of SPS and other autoantibody-mediated neurological disorders, and the research evidence provides another possibility for treating patients with anti-GAD-related disorders (48). The gene discussed is GAD1; the disease is stiff-person syndrome.